Multiple ways of targeting APOBEC3–virion infectivity factor interactions for anti-HIV-1 drug development
- 19 October 2009
- journal article
- review article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 30 (12) , 638-646
- https://doi.org/10.1016/j.tips.2009.09.006
Abstract
No abstract availableFunding Information
- National Cancer Institute
- National Institutes of Health (HHSN261200800001E)
This publication has 128 references indexed in Scilit:
- An Extended Structure of the APOBEC3G Catalytic Domain Suggests a Unique Holoenzyme ModelJournal of Molecular Biology, 2009
- Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3GThe EMBO Journal, 2009
- The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradationVirology, 2008
- Functional domain organization of human APOBEC3GVirology, 2008
- Characterization of Conserved Motifs in HIV-1 Vif Required for APOBEC3G and APOBEC3F InteractionJournal of Molecular Biology, 2008
- Evolution of HIV-1 Isolates that Use a Novel Vif-Independent Mechanism to Resist Restriction by Human APOBEC3GCurrent Biology, 2008
- The Interferon-Induced Protein BST-2 Restricts HIV-1 Release and Is Downregulated from the Cell Surface by the Viral Vpu ProteinPublished by Elsevier ,2008
- APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cellsVirology, 2008
- Mass spectrometry analysis of HIV‐1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivityProteins-Structure Function and Bioinformatics, 2007
- Functional domains of APOBEC3G required for antiviral activityJournal of Cellular Biochemistry, 2004